Nasdaq

Beam Therapeutics to Present Updated Data on BEAM-101 in Sickle Cell Disease at EHA2025 Conference

Beam Therapeutics will present new BEAM-101 data for sickle cell disease at EHA2025, detailing safety and efficacy in 17 patients. Beam Therapeutics Inc. has announced that it will present updated ...
MarketWatch

CORRECTION -- Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer

The MarketWatch News Department was not involved in the creation of this content. In the news release, Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to ...
Nasdaq

Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the ...
Clinical Trials Arena on MSN

Zelluna secures MHRA approval to begin ZIMA-101 trail

Initial clinical data are anticipated from mid-2026.
Seeking Alpha

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (BEAM) (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced ...
Monthly Prescribing Reference

Cell Therapy MDR-101 Produces Functional Immune Tolerance in Kidney Transplant Recipients

Seventy-five percent reached the primary study end point of immunosuppression-free for more than 2 years. HealthDay News — Kidney transplant recipients receiving the investigational cellular product ...